Skip to main content

HEALTH

  • NABP white paper stresses drug supply chain security

    NEW YORK — Keeping counterfeit and diverted drugs out of the U.S. drug supply chain will require closing vulnerable regulatory gaps that risk letting them in, according to a new report by the National Association of Boards of Pharmacy.

  • NIH to investigate whether vitamin D helps prevent Type 2 diabetes

    BETHESDA, Md. — Researchers have begun the first definitive, large-scale clinical trial to investigate if a vitamin D supplement helps prevent or delay Type 2 diabetes in adults who have prediabetes and are at high risk for developing Type 2. Funded by the National Institutes of Health, the study is taking place at about 20 study sites across the United States, the agency announced Monday.

  • Study: Vitamin D deficiency may increase a child's risk of anemia

    BALTIMORE — Low levels of vitamin D appear to increase a child's risk of anemia, according to new research led by investigators at the Johns Hopkins Children's Center. The study, published online Oct. 10 in the Journal of Pediatrics, is believed to be the first one to extensively explore the link between the two conditions in children.

  • Overall, Okinawa Life passes muster with ERSP

    NEW YORK — The Electronic Retailing Self-Regulation Program last week determined that Kowa Health Care America can support general performance claims for Okinawa Life, a dietary supplement marketed as providing a variety of health benefits. 

  • Study finds 1-in-50 at risk of severe allergic reactions

    WASHINGTON — Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

    According to the study, severe, life-threatening allergic reactions known as anaphylaxis are common in the United States, occurring in about 1.6% of the population. The rate, the study said, is probably higher, and closer to 5.1%. The study was published in the Journal of Allergy and Clinical Immunology.

  • Bayer HealthCare consolidates office buildings to new Whippany, N.J., facility

    WHIPPANY, N.J. — Bayer HealthCare last week moved into its new U.S. headquarters on a 94-acre campus here, consolidating Bayer HealthCare's operations that previously operated from Morristown, Montville and Wayne, N.J., and Tarrytown, N.Y., into one location.  

    Housed in two buildings connected by a five-story glass atrium, the 700,000-sq.-ft. office space features state-of-the-art technology and a modern open design for the approximately 2,400 employees now based at the new location.

  • Staples survey: More employees reporting to duty sick

    FRAMINGHAM, Mass. — Nearly 90% of office workers come to work even when they know they are sick, according to the fourth annual Flu Season Survey from Staples. The findings show a growing trend when compared to last year’s findings indicating 80% of workers come to work sick, and up from 60% in the 2011 Staples survey.

  • NAD recommends Maximum Human Performance tone down its advertising for MYO-X Myostatin Inhibitor

    NEW YORK — The National Advertising Division last week recommended that Maximum Human Performance, which markets the dietary supplement MYO-X Myostatin Inhibitor, discontinue the advertising claims and testimonials at issue in NAD’s review.

X
This ad will auto-close in 10 seconds